The World Health Organization (WHO) has released its first-ever comprehensive global guidelines addressing child and adolescent obesity, establishing a clear…
Read More
Navigating the Challenge of GLP-1RA Non-Responders in Obesity and Metabolic Disease Management
The rapid global adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has fundamentally transformed the therapeutic landscape for obesity and type…
Read More
Evaluating ERS 2026 Insights on Biologic Therapies for Obesity-Driven Asthma Phenotypes
The intersection of metabolic disease and respiratory medicine has emerged as one of the most critical frontiers in modern clinical…
Read More
Novo Nordisk Drops Nordisk in Major Rebrand to Modernise Identity Amid Fierce Competition in Obesity and Diabetes Markets
The pharmaceutical landscape is undergoing a quiet yet profound visual and strategic evolution, and one of its most prominent titans…
Read More
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Advertising of Obesity Drugs
The escalating rivalry between pharmaceutical giants Novo Nordisk and Eli Lilly has reached a new legal frontier, with Novo Nordisk…
Read More
Novo Nordisk Secures European Approval for Oral Wegovy, Bolstering First-Mover Advantage in Obesity Pill Market
Novo Nordisk has solidified its pioneering position in the burgeoning market for oral obesity medications with the European Commission’s marketing…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company utilized the prestigious platform of the American Diabetes Association’s (ADA) annual meeting to unveil groundbreaking Phase…
Read More
Eli Lilly and Oura Health Forge Strategic Alliance to Pioneer Integrated Obesity Care
The landscape of obesity treatment is undergoing a profound transformation, moving beyond purely pharmaceutical interventions to embrace a holistic ecosystem…
Read More
